Overview

INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

Status:
Terminated

Trial end date:
2021-06-29

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and antitumor activity of INCB001158 in combination with daratumumab SC, compared with daratumumab SC alone, in participants with relapsed or refractory multiple myeloma.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Incyte Corporation

Treatments:

Antibodies, Monoclonal
Daratumumab